x

Posted 04 February, 2021

Merck & Co., Inc. appointed new CEO

CEO Change detected for ticker NYSE:MRK in a 8-K filed on 04 February, 2021.


  Merck & Co., Inc. (the "Company") announced that Kenneth C. Frazier, the Company's Chairman and Chief Executive Officer will retire as Chief Executive Officer, effective June 30, 2021.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Merck & Co., Inc.
Health Care/Life Sciences • Pharmaceuticals
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Market Cap
$314B
View Company Details
Merck & Co., Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b)(c)(d)


Merck & Co., Inc. (the "Company") announced that Kenneth C. Frazier, the Company's Chairman and Chief Executive Officer will retire as Chief Executive Officer, effective June 30, 2021. After his retirement, Mr. Frazier will continue as Executive Chairman of the Company for a transition period to be determined by the Board of Directors ("Board").


In addition, on February 1, 2021, the Board unanimously elected Robert M. Davis, age 54, the Company's current Executive Vice President, Global Services and Chief Financial Officer, to serve as President of the Company, effective April 1, 2021, and as the Chief Executive Officer and a director of the Company, effective July 1, 2021.


On February 4, 2021, the Company issued a press release (the "Press Release") announcing the foregoing. The Press Release is attached as Exhibit 99.1 and incorporated herein by reference.